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Transient receptor potential (TRP) cation channel subfamily M
member 3 (TRPM3), a member of the TRP channel superfamily, was
recently identified as a nociceptor channel in the somatosensory
system, where it is involved in the detection of noxious heat;
however, owing to the lack of potent and selective agonists, little
is known about other potential physiological consequences of the
opening of TRPM3. Here we identify and characterize a synthetic
TRPM3 activator, CIM0216, whose potency and apparent affinity
greatly exceeds that of the canonical TRPM3 agonist, pregneno-
lone sulfate (PS). In particular, a single application of CIM0216
causes opening of both the central calcium-conducting pore and
the alternative cation permeation pathway in a membrane-delimited
manner. CIM0216 evoked robust calcium influx in TRPM3-expressing
somatosensory neurons, and intradermal injection of the compound
induced a TRPM3-dependent nocifensive behavior. Moreover,
CIM0216 elicited the release of the peptides calcitonin gene-
related peptide (CGRP) from sensory nerve terminals and insulin
from isolated pancreatic islets in a TRPM3-dependent manner.
These experiments identify CIM0216 as a powerful tool for use
in investigating the physiological roles of TRPM3, and indicate that
TRPM3 activation in sensory nerve endings can contribute to
neurogenic inflammation.
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Transient receptor potential (TRP) channels represent a largeand diverse family of nonselective cation channels that re-
spond to a wide range of chemical and physical stimuli and
biophysical properties (1). TRP cation channel subfamily M
member 3 (TRPM3), a calcium-permeable nonselective cation
channel (2), is a typical example of a polymodally gated TRP
channel, in that it can be activated by ligands, such as pregnenolone
sulfate (PS) and nifedipine, as well as by heat and membrane de-
polarization (3, 4). Interestingly, recent evidence indicates that
combined stimulation with PS and clotrimazole (Clt) leads to the
activation of two distinct permeation pathways in TRPM3: the
central pore, which is Ca2+-permeable and carries an outwardly
rectifying current, and an alternative ion permeation pathway that
mediates an inwardly rectifying monovalent cation current (5).
TRPM3 is highly expressed in somatosensory neurons, where
it plays decisive roles in the nocifensive response to PS and heat,
as well as in the development of heat hyperalgesia during in-
flammation (3, 6). In these neurons, TRPM3 is frequently coex-
pressed with TRPA1 and TRPV1, two TRP channels that have
emerged as key regulators of neurogenic inflammation by triggering
neuropeptide release from sensory nerve endings (7, 8). Whether
activation of TRPM3 can also initiate the release of neuropeptides,
such as substance P or calcitonin gene-related peptide (CGRP),
which elicit vasodilation, vascular leakage, and other responses in
peripheral cell types, is unclear, however. In addition, TRPM3 is
expressed in pancreatic beta cells, where it is involved in controlling
insulin release (4), as well as in various tissues, including brain, pi-
tuitary gland, eye, kidney, and adipose tissue (reviewed in ref. 9).
The physiological roles of TRPM3 in these tissues remain only
poorly understood, owing in part to the lack of potent and spe-
cific pharmacologic tools to modulate its action in vitro and
in vivo.
Here we describe the identification and characterization of
a TRPM3 agonist, CIM0216, with a potency that greatly exceeds
that of currently used agonists. This compound has the unique
property to open both ion permeation pathways of TRPM3
without the requirement of other channel modulators. We fur-
ther demonstrate that CIM0216 acts in a TRPM3-dependent
manner to induce pain and evoke neuropeptide release from
sensory nerve terminals in the skin, and also to release insulin
from pancreatic islets. Collectively, these findings provide a novel
powerful tool for use in further studies of the physiological func-
tions of TRPM3, and identify TRPM3 as a novel player in neu-
rogenic inflammation.
Results
CIM0216 Selectively Activates TRPM3 in Stably Transfected HEK293 Cells.
A diverse small-molecule library was screened for compounds
that modulate TRPM3-mediated Ca2+ responses in HEK293
cells stably expressing murine TRPM3 (HEK-TRPM3 cells), as
described previously (3). One such compound, CIM0216, was found
to evoke robust increases in intracellular Ca2+ concentration in
HEK-TRPM3 cells and was investigated further. The structure
of CIM0216 [racemate of 2-(3,4-dihydroquinolin-1(2H)-yl)-N-
(5-methylisoxazol-3-yl)-2-phenylacetamide] is presented in Fig. 1A.
Significance
The cation channel TRPM3 is highly expressed in the sensory
system, where it plays a key role in the detection of noxious
heat and the development of inflammatory heat hypersensi-
tivity. Our understanding of the physiological role of TRPM3 in
the sensory system and other tissues is hampered by the lack
of potent pharmacologic tools, however. This study describes
CIM0216, a small-molecule TRPM3 agonist. Our results indicate
that CIM0216 is much more potent than established TRPM3
agonists, particularly owing to its ability to open two distinct
cation-permeable pores in TRPM3. Using CIM0216 as a phar-
macologic tool, we reveal that activation of TRPM3 evokes the
release of calcitonin gene-related peptide from sensory nerve
terminals and of insulin from pancreatic islets.
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In HEK-TRPM3 cells, CIM0216 elicited a dose-dependent
Ca2+ response [negative logarithm of the EC50 value (pEC50) =
0.77 ± 0.1 μM], which was not observed in nontransfected
HEK293 cells (Fig. S1). The endogenous TRPM3 activator
pregnenolone sulfate (PS) also elicited a dose-dependent Ca2+
response, typified by a smaller Ca2+ influx and a fivefold lower
potency (pEC50 = 3.0 ± 0.1 μM; n = 2) (see also ref. 4) compared
with CIM0216 (Fig. 1B). In the presence of 40 μM PS, the dose
dependency of CIM0216 shifted to a lower concentration in
HEK-TRPM3 cells (pEC50 = 42 ± 0.6 nM CIM0216 in the
presence of PS; Fig. 1B). Single-cell FURA2-ratiometric Ca2+
imaging revealed a robust increase in intracellular Ca2+ con-
centration (1,145 ± 26 nM; n = 603 from at least three in-
dependent measurements) on stimulation with 1 μMCIM0216 in
all HEK-TRPM3 cells. These responses were not observed in
nontransfected HEK cells (n = 166) or in the absence of extra-
cellular Ca2+ (Fig. 1C and Fig. S1).
In whole-cell patch-clamp experiments, stimulation of HEK-
TRPM3 cells evoked robust, doubly rectifying currents (Fig. 1 D
and E), which were not observed in nontransfected naïve HEK
cells (Fig. 1F) and were blocked by the TRPM3 inhibitor iso-
sakuranetin (5 μM; Fig. 1G) (10). The effect of CIM0216 on
TRPM3 currents was concentration-dependent; however, in the
patch-clamp experiments, saturating responses were never achieved
within the solubility range of CIM0216 and the time period of the
experiment. A similar dose-dependent activation for CIM0216 was
obtained for HEK293 cells transiently transfected with human
TRPM3 (n = 5) (Fig. S2 and Table 1). Remarkably, the PS-
induced current increases in HEK-TRPM3 cells at saturating
PS concentrations (100 μM) were already obtained at a 200-fold
lower concentration of CIM0216 (0.5 μM), indicating that com-
pared with PS, CIM0216 has significantly greater efficacy for ac-
tivating TRPM3 (Fig. 1I).
To evaluate the specificity of CIM0216 for TRPM3, we ex-
amined its effects on all members of the TRPM subfamily. When
tested at a concentration of 10 μM, CIM0216 had no stimulating/
blocking effect on TRPM1 (11), TRPM4, TRPM6, or TRPM7
Fig. 1. CIM0216 activates TRPM3 in HEK-TRPM3 cells. (A) Chemical structure of CIM0216. (B) [Ca2+]I was monitored using Fluo-4 AM in HEK-TRPM3 cells
before and after the addition of different concentrations of PS (black), CIM0216 (blue), and PS plus CIM0216 (red). Responses were measured as peak increases
in fluorescence minus basal, expressed relative to a maximum PS response, and are given as mean ± SEM. n = 2. (C) Time course of Ca2+ imaging mea-
surements in HEK293 cells stably expressing TRPM3 (HEK-TRPM3 cells) and nontransfected (NT) HEK293 cells during application of PS (40 μM) and CIM0216
(1 μM). (D) Time course at ±80 mV of a whole-cell patch-clamp recording on HEK-TRPM3 cells treated with PS (40 μM) and CIM0216 (1 μM), (E) I–V traces
corresponding to the time points indicated in D. (F) Time course at ±80 mV of a whole-cell patch-clamp recording showing the application of PS and CIM0216
on nontransfected HEK293 cells. Mean ± SEM values are shown; n = 5. (G) Time course at ±80 mV of whole-cell patch-clamp measurement on HEK-TRPM3 cells
presenting the block of CIM0216-induced currents by isosakuranetin (5 μM). (H) Time course at ±80 mV of a patch-clamp recording in whole-cell configuration
showing CIM0216 dose-dependent activation of TRPM3 currents in HEK-TRPM3 cells. (I) Dose–response curves of CIM0216 (blue) and PS (black) in HEK-TRPM3.
n = 5. Unless indicated otherwise, standard compound concentrations were 40 μM for PS and 1 μM for CIM0216.
Table 1. CIM0216 selectivity
Channel Activation Block at 10 μM
hTRPM1 − −
hTRPM2 − + (17%)
mTRPM3 +++ −
hTRPM3 +++ −
hTRPM4 − −
hTRPM5 − + (34%)
hTRPM6 − −
hTRPM7 − −
hTRPM8 − ++ (61%)
mTRPA1 + (15 ± 8% of MO
response at −80 mV)
−
This table represents the activating/ blocking activity of CIM0216 toward
mouse (m) and human (h) TRPM3 and to other TRPM family members, as
well as other sensory TRP channels. In all conditions, the selectivity of
CIM0216 was tested by application of 10 μM CIM0216 to HEK293 cells stably
expressing hTRPM4 or mTRPM5 or transiently transfected with hTRPM1,
hTRPM2, hTRPM6, mTRPM7, hTRPM8, or hTRPV1. The selectivity of CIM0216
toward TRPA1 was tested at a concentration of 10 μM and at −80 mV in CHO
cells stably expressing mTRPA1.
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currents; however, a small blocking effect of CIM0216 was ob-
served after activation of TRPM2 (16.6% block) and TRPM5
(33.5% block) (Fig. S3 and Table 1). We also tested CIM0216’s
specificity toward other sensory TRPs and observed no detect-
able effect on human TRPV1 and TRPM8 channel activation at
a concentration of 10 μM (Fig. S4). In contrast, CIM0216 in-
duced a significant block of 61 ± 5% of the menthol-induced
currents in TRPM8-transfected HEK293 cells. In CHO cells
stably expressing murine TRPA1, a significant but minor in-
crease in current amplitude (<10% increase at −80 mV relative
to the response to stimulation with 100 μM allyl isothiocyanate)
was observed after stimulation by 100 μM CIM0216 (Fig. S4 and
Table 1).
CIM0216 and Clt Have Common Features for TRPM3. The activation
of TRPM3 currents by CIM0216 developed over time, reaching
maximal activation within ∼100 s (Fig. 1 D, G, and H), and then
faded out gradually after washout, with a mean ± SEM time
constant of 208 ± 12 s (n = 16). This finding contrasts with the
rapidly reversible agonistic effect of PS (Fig. 2A). Whereas
pretreatment with Clt (10 μM) led to strong potentiation of PS-
induced TRPM3 currents (Fig. 2 A, B, G, and H) (5), it had no
amplifying effect on the CIM0216-induced TRPM3 current (Fig.
2 C and D). In contrast, the CIM0216-induced TRPM3 outward
current was mainly blocked by 10 μM Clt (76.9 ± 3% inhibition
at −80 mV and 67.6 ± 5% inhibition at +80 mV; n = 4), possibly
suggesting competition between Clt and CIM0216 for a similar
binding site (Fig. 2G). Conversely, measurement of intracellular
Ca2+ in HEK-TRPM3 cells revealed a dose-dependent potenti-
ation of CIM0216 on PS stimulation (pEC50 = 42 ± 0.6 nM for
CIM0216 in the presence of PS) (Fig. 1B).
These experiments clearly show that the potentiation of PS-
induced Ca2+ influx by CIM0216 occurs at much lower con-
centrations than in direct activation. In addition, incubation
with a low dose of CIM0216 (0.1 μM) in patch-clamp experi-
ments caused a strong potentiation of the currents evoked by PS
(37 ± 8-fold potentiation at −150 mV and 10 ± 3-fold potenti-
ation at +150 mV; n = 5), which by itself does not induce ap-
preciable activation of TRPM3 (Fig. 2 E and F). Thus, CIM0216
has greater potency for potentiating PS-induced currents than
for activating TRPM3 currents.
A similar potentiation of PS-induced TRPM3 currents was
observed for Clt (Fig. 2H). On stimulation by CIM0216, current–
voltage (I–V) relationships showed double rectification, with
marked inward currents at strongly hyperpolarizing potentials
(Figs. 1 and 2), similar to that described for currents activated by
the combination of Clt and PS (5). Quantifying the rectification
as the ratio of the absolute current amplitude at −150 mV and
+150 mV (ratio−150/+150) yielded a rectification score of 0.58 ±
0.02 for currents in the presence of CIM0216, significantly dif-
ferent from the rectification score of PS-induced currents (0.10 ±
0.01; P < 0.001) but comparable to that seen in the combined
presence of PS and Clt (Fig. 3A).
Plotting the outward vs. inward current amplitudes of the
TRPM3 currents showed a linear correlation (R2 = 0.949) be-
tween outward and inward current amplitudes over a range of
CIM0216 concentrations, indicating that the rectification score is
not strongly dependent on CIM0216 concentration (Fig. S5).
When N-methyl-D-glucamine (NDMG+) was substituted for Na+
in the extracellular solution, TRPM3 currents evoked by
CIM0216 lacked an inward component (Fig. 3B). This indicates
that the inward current is carried exclusively by cations, and that
NMDG+ is not able to permeate the channel under these cir-
cumstances. Inside-out patches of HEK-TRPM3 cells showed
a current increase after stimulation by CIM0216, indicating that
CIM0216 can activate TRPM3 in a membrane-delimited manner
(Fig. 3 C and D).
Conductance–voltage (G–V) curves in the presence of CIM0216
were biphasic, showing a minimal conductance at around −50 mV
and increasing conductance at more depolarizing and hyperpolar-
izing potentials, which saturated at around +200 mV and −250 mV,
respectively (Fig. 3 E and F). Identical biphasic G–V curves can be
observed in the combined presence of PS and Clt (5). To further
investigate the potency of CIM0216 to activate biphasic G–V curves
in TRPM3, we analyzed mutant channels with mutations in the S4
domain (W982R) and the TRPM3 pore domain (E1057C) (5).
Stimulation by CIM0216 induced G–V currents identical to the PS-
induced G–V currents in HEK293 cells overexpressing W982R
(Fig. S6). Conversely, HEK293 cells overexpressing the E1057C
mutant showed overlapping G–V currents at depolarizing potentials
for PS and CIM0216 stimulation. However, at hyperpolarizing po-
tentials, G–V currents were observed only after CIM0216 stimula-
tion (Fig. S6). Taken together, the foregoing data indicate that the
effects of a single CIM0216 application on TRPM3 are similar to
those of the combined application of PS and Clt.
Fig. 2. CIM0216s modulation of PS-induced TRPM3 currents shows high
similarity to the Clt-induced effects. (A) Time course at ±80 mV of a whole-
cell patch-clamp recording showing the effect of Clt (10 μM) on PS (40 μM)-
induced HEK-TRPM3 cells. (B) I–V relationship corresponding to the time
points indicated in A. (C) Time course at ±80 mV of a whole-cell patch- clamp
recording showing the effect of Clt (10 μM) on CIM0216 (1 μM) stimulation in
HEK-TRPM3–expressing cells. (D) I–V relationship corresponding to the time
points indicated in C. (E) Time course at ±80 mV of whole-cell patch-clamp
measurement on HEK-TRPM3 cells after stimulation by PS (40 μM) and
CIM0216 (0.1 μM) plus PS (40 μM). (F) I–V relationship corresponding to the
time points indicated in E. (G) Mean current increase at +80 mV and −80 mV
in HEK-TRPM3 cells after stimulation by PS (40 μM) and CIM0216 (1 μM) in
the absence (black bar) and presence (gray bar) of Clt (10 μM). n = 5.
(H) Relative potentiation of the PS-induced currents after incubation by Clt
(10 μM) and CIM0216 (0.1 and 1 μM) of the inward (−150 mV; black bars) and
outward (+150 mV; gray bars) currents. n = 4.
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Given that Clt is able to open the alternative ion permeation
pathway in TRPM3 in the presence of PS (5), we considered the
possibility that a single application of CIM0216 could open both
ionic pores, the central pore and the alternative cation perme-
ation pathway, independent of Clt. Several lines of evidence
support this hypothesis. First, the CIM0216-induced inward
current is more resistant to Ca2+-dependent desensitization, a
process that leads to rapid decay of the outwardly rectifying
TRPM3 current (75 ± 7% block at +80 mV), whereas the inward
currents showed no Ca2+-dependent desensitization (Fig. 4 A
and B). Second, the nonspecific pore blocker La3+ isolated the
inwardly rectifying current component. Stimulation of HEK-
TRPM3 cells by CIM0216 (1 μM) in the presence of the pore
blocker La3+ (100 μM) induced a stable inward rectifying cur-
rent. An inwardly and outwardly rectifying current component
was observed after removal of the La3+ (Fig. 4 C–E). Of note, the
G−V curve of the inward current in the presence of La3+ was
shifted to more negative voltages (by 13 ± 6 mV) compared with
control values (Fig. S7). This slight shift in apparent voltage
dependence may reflect a low-affinity block of the alternative ion
permeation pathway, as has been described for the gating-pore
current in NaV1.4, interactions of La
3+ with membrane surface
charges, and/or an effect of La3+ on channel gating (12, 13).
Third, the La3+-insensitive inward current exhibited identical
properties of the alternative permeation pathway activated by PS
in the presence of Clt, including (i) strong inward rectifica-
tion, (ii) inhibition by extracellular Mg2+ and Ca2+ (Fig. 4 F andG),
and (iii) increased permeability for guanidinium compared with
Na+ when all extracellular Na+ was replaced by guanidinium
(Fig. 4H). Taken together, these findings indicate that stimula-
tion with CIM0216 by itself is able to mimic the effects of
coapplication of PS plus Clt on TRPM3, namely simultaneous
opening of the central pore and the alternative permeation
pathway (Fig. S8).
Synergistic Effects of Heat and CIM0216 on TRPM3. TRPM3 has been
identified as a temperature-sensitive ion channel that is steeply
activated by heating (3). Previous work on other thermosensi-
tive TRP channels has demonstrated synergistic effects between
chemical agonists and thermal stimuli; for example, PS responses
Fig. 3. CIM0216-induced TRPM3 currents show high similarity to PS + Clt-
induced TRPM3 currents. (A) Rectification pattern of PS, PS + Clt, and
CIM0216-induced TRPM3 currents in HEK-TRPM3 cells, derived by plotting
the currents at +150 mV against the currents at −150 mV. (B) Time course
at ±80 mV of a whole-cell patch-clamp recording on HEK-TRPM3 cells. At
the indicated time points, all Na+ was replaced by NMDG+. (C ) Time course
at ±80 mV of a patch- clamp recording performed in the inside-out con-
figuration on HEK-TRPM3 cells during application of CIM0216 (1 μM). (D) I–V
traces corresponding to indicated time points in C. (E ) Current traces ob-
tained with a step protocol in HEK-TRPM3 cells after stimulation by PS
(black; 40 μM), PS (40 μM) + Clt (10 μM; red), and CIM0216 (1 μM; blue).
(F ) G–V plot for CIM0216. The fit was obtained with a Boltzmann func-
tion (n = 6).
Fig. 4. Desensitization and permeation properties of the alternative ion
permeation pathway. (A) Time course at ±80 mV of a whole-cell patch-clamp
recording on HEK-TRPM3 cells during application of CIM0216 (1 μM). At the
indicated time points, the extracellular bath concentration was replaced by
a solution containing 1 mM [Ca2+]ex. (B) I–V relationship at the time points
indicated in A. (C) Time course of a whole-cell patch-clamp recording on
HEK-TRPM3 cells at ±150 mV showing CIM0216-induced currents in the
presence and absence of the pore blocker La3+. (D) I–V traces corresponding
to the indicated time points in C. (E) Current traces obtained with an in-
dicated step protocol from +200 to −200 mV in +20-mV steps under the
condition of costimulation with CIM0216 and La3+. (F and G) I–V traces
obtained during simultaneous application of CIM0216 and La3+ in the
presence of different concentrations of Ca2+ (F) or Mg2+ (G). (Insets) Mean
current normalized to the maximum Na+ current in the absence of Ca2+ (F)
or Mg2+ (G). n ≥5. (H) I–V traces obtained during simultaneous application of
CIM0216 and La3+ in the presence of Na+ and guanidinium (Gua+). Unless
indicated otherwise, standard compound concentrations were 40 μM for PS,
100 μM for La3+, and 1 μM for CIM0216.
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in TRPM3 are potentiated at high temperatures (3). We observed
a similar synergism of heat and CIM0216 on TRPM3. We found
that increasing the temperature from room temperature (22 °C) to
37 °C strongly potentiated CIM0216 responses in Ca2+ imaging
experiments. Interestingly, CIM0216 concentrations as low as
100 nM, which are subthreshold at room temperature, evoked
robust responses at 37 °C (Fig. 5 A and B). Taken together, these
data demonstrate that the activating effect of CIM0216 on TRPM3
is temperature-dependent.
CIM0216 Activates TRPM3 Channels in Somatosensory Neurons and
Evokes Pain. Previous work revealed that TRPM3 is functionally
expressed in mouse dorsal root ganglia (DRG) and trigeminal
ganglion neurons (TGN) (3). To test whether CIM0216 is able to
specifically activate endogenous TRPM3, we first compared in-
tracellular Ca2+ responses to stimulation with PS and CIM0216
in freshly isolated somatosensory neurons derived from DRG
and TGN. Stimulation with CIM0216 evoked robust and re-
versible calcium signals (ΔCa2+ = 357 ± 14 nM) in 57% of DRG
(311 of 543) (Fig. 6 A and D) and 62% of TGN (197 of 317)
isolated from wild-type (WT) mice. The majority (96%) of the
CIM0216-responsive neurons were responsive to PS as well (Fig.
6 A and E). Importantly, the fraction of CIM0216-sensitive
neurons was drastically decreased in DRG and TGN prepara-
tions from TRPM3−/− mice, whereas the fraction of neurons that
responded to allyl isothiocyanate (MO) (68% in WT and 63% in
TRPM3−/−), an activator of TRPA1 (14), or to capsaicin (73% in
WT and 77% in TRPM3−/−), an agonist of TRPV1 (15), were
not changed significantly (Fig. 6 B and D). The small number
of TRPM3−/− neurons that responded to CIM0216 stimulation
(11% of all neurons) were always reactive to MO stimulation,
and could be blocked in the presence of the TRPA1 inhibitor
HC030031 (16) (Fig. S9), possibly suggesting that these responses
reflect the very mild agonistic effect of CIM0216 on TRPA1 (Fig.
S4). A high fraction of CIM0216 responders (55%; 110 of 200) was
found in DRG neurons obtained from Trpa1-deficient mice (Fig. 6
C and D). In 94% of all CIM0216 responders in WT mice, the
CIM0216-induced Ca2+ increase could be blocked by application
of the TRPM3 blocker isosakuranetin (5 μM). The small subset
of neurons that still responded to CIM0216 in the presence of
isosakuranetin was responsive to MO as well (Fig. 6 E and F).
In whole-cell current recordings in DRG and TGN from
WT mice, CIM0216 activated a significant current increase
(13.0 ± 3 pA/pF at –80 mV and 17.3 ± 5 pA/pF at +80 mV) in
62% of the neurons (n = 13) (Fig. 7 A and B). CIM0216-induced
currents showed a doubly rectifying I–V relationship (ratio−120/+120 =
0.47 ± 0.06; n = 8). Application of La3+ induced 100% blockage
of the outward current, but only partial blockage of the inward
Fig. 5. Synergistic effects of heat and CIM0216 on TRPM3. (A) Typical
examples of the intracellular calcium increase induced by low doses of
CIM0216 (0.1 μM) applied at room temperature (22 °C) and 37 °C in HEK-
TRPM3 cells. (B) Bar diagram showing average Ca2+ increases in response to
CIM0216 (0.1 μM), heat stimulus (37 °C), and CIM0216 (0.1 μM) at 37 °C. The
open bar illustrates the calculated summation of CIM0216 and heat re-
sponse. The red bar shows the measured value of combined application of
heat and CIM0216, illustrating the supra-additive effect of heat on CIM0216
stimulation. n > 42 cells from at least three independent measurements.
Data are presented as mean ± SEM.
Fig. 6. Reduced CIM0216 responses in TRPM3-deficient sensory neurons. (A–C) Representative traces showing typical patterns of intracellular Ca2+ in DRG
and TGN from control animals Trpm3+/+ (A), Trpm3−/− (B), and Trpa1−/− (C) mice in response to PS (20 μM), CIM0216 (1 μM), MO (100 μM), capsaicin (Cap;
1 μM), and K+ (50 mM). (D) Percentage of sensory neurons derived from TRPM3+/+, TRPM3−/−, and TRPA1−/− mice responding to stimulation by PS (20 μM),
CIM0216 (1 μM), MO (100 μM), and capsaicin (1 μM). (E) Percentage of sensory neurons responding to CIM0216 in preparations from TRPM3+/+, TRPM3−/−, and
TRPA1−/− mice. Different colors correspond to the different subtypes of CIM0216 responders based on PS and MO sensitivity. (F) Representative traces
showing typical response patterns of intracellular Ca2+ in DRG and TGN from control animals in response to CIM0216 (1 μM), MO, and high K+. At the in-
dicated time bar, the TRPM3 blocker isosakuranetin (5 μM) was added.
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current (Fig. 7 A and B). These properties are identical to those
observed for CIM0216 stimulation in a TRPM3-overexpression
system (Fig. 4C) and for coapplication of PS plus Clt (5).
TRPM3-deficient neurons showed no detectable current re-
sponse to CIM0216 stimulation (Fig. 7C) (n = 12). Note that in
both Trpm3+/+- and Trpm3−/−-derived neurons, application of
CIM0216 induced an inhibition of outward current of varying
amplitude. This blockage was never observed in Ca2+ imaging
experiments, however, suggesting that this small inhibitory effect
is not sufficient to induce excitation of sensory neurons.
To investigate whether CIM0216 can activate TRPM3 in vivo,
we tested for nocifensive behavior in WT and TRPM3−/− mice
following injection of CIM0216 into the plantar skin of the hind
paw. Injection of CIM0216 (2.5 nmol) in the hind paw evoked
strong nocifensive behavior (i.e., paw licking and lifting) in
control mice (Fig. 7D). The nocifensive behavior to CIM0216
was remarkably more exhaustive compared with intraplantar
injection of a sixfold-higher dose of PS (15 nmol). TRPM3−/−
mice completely lacked this nocifensive response to CIM0216
and PS, whereas injection of the TRPV1-agonist capsaicin (0.5
nmol) evoked a normal nocifensive behavior in both genotypes
(Fig. 7D). Taken together, these findings indicate that CIM0216
induced pain in a TRPM3-dependent manner, with a pain re-
sponse more robust than that to PS.
Neuropeptide Release by CIM0216 Depends on TRPM3 Activity. The
sensory TRP channels TRPA1 and TRPV1 participate in neu-
rogenic inflammation and vasodilation, by initiating the release
of calcitonin gene-related peptide (CGRP) and substance P (7, 8,
17). Previous results have shown that PS responsiveness, like
capsaicin responsiveness (18), is restricted almost exclusively to
small-diameter (<25 μm) DRG neurons, which are known to
include unmyelinated nociceptor neurons (3). In addition, a
large subpopulation of PS-responsive DRG neurons was also
responsive to capsaicin and MO, illustrating a functional coex-
pression of TRPM3 and TRPV1/ TRPA1.
To test whether activation of TRPM3 in nerve terminals also
leads to neuropeptide release and neurogenic inflammation, we
performed release experiments using isolated mouse hind paw
skin. The skin is densely innervated with peptidergic CGRP
containing nerve endings. A 5-min incubation of the skin with PS
produced a dose-dependent release of CGRP, which was absent
in skin preparations derived from TRPM3−/− knockout mice
(Fig. 8A). A similar PS-induced CGRP release was observed in
TRPV1−/− and TRPA1−/− mice (Fig. S10). In addition, the novel
TRPM3 agonist CIM0216 caused a significant, dose-dependent
increase of cutaneous CGRP release in WT animals, which was
largely reduced in the presence of the antagonist isosakuranetin
(5 μM) and was absent in skin preparations of Trpm3-deficient
mice (Fig. 8 B and C), suggesting a selective action of the
compound on TRPM3. In addition, CIM0216 evoked compara-
ble CGRP release in TRPV1−/− TRPA1−/− double-knockout
mice as in WT mice (Fig. S10). Collectively, these results indicate
that chemical ligands such as CIM0216 can activate TRPM3 in
sensory nerve terminals, leading to neuropeptide release and
acute neurogenic inflammation.
CIM0216 Activates TRPM3 Channels in Pancreatic Beta Cells and
Releases Insulin. TRPM3 expression has been described in the
pancreas, and stimulation of pancreatic islets with PS evokes
insulin secretion (4). To evaluate the effect of CIM0216 in
pancreatic islets, we performed Ca2+ imaging on isolated pan-
creatic islets and used PS and CIM0216 as specific TRPM3
activators. Stimulation by PS and CIM0216 induced an increase
in fluorescence in all islets derived from control mice (n = 5)
(Fig. 9 A and C). In contrast, no Ca2+ increase was observed in
pancreatic islets derived from Trpm3-deficient mice (n = 13)
after stimulation by CIM0216 (Fig. 9B). As a positive control,
a high-K+ solution (30 mM) was applied at the end of every
experiment, and no difference in fluorescence increase was ob-
served in islets derived from control and Trpm3-deficient mice
(Fig. 9C).
In whole-cell patch-clamp experiments on isolated WT pan-
creatic cells, stimulation by PS induced an outwardly rectifying
current (1 ± 1 pA at –80 mV and 47.3 ± 14 pA at +80 mV) in
100% of the pancreatic cells (n = 6) that could be blocked in the
presence of La3+ (Fig. 9 D, E, and H); however, stimulation by
CIM0216 induced a doubly rectifying current (81.9 ± 19 pA at
–80 mV and 539.6 ± 159 pA at +80 mV) in all of the pancreatic
cells (n = 8). Incubation by La3+ induced a block of the outward
current (78% inhibition), whereas the inward current remained
mainly unaffected (37% inhibition) (Fig. 9 D and F). In contrast,
PS and CIM0216 stimulation did not induce a current increase
in Trpm3−/−-derived pancreatic cells (Fig. 9 G and H).
An increase in intracellular Ca2+ causes exocytosis of large
vesicles and thereby releases insulin (19). Islets incubated with
PS or CIM0216 showed a dose-dependent increase in insulin
release compared with vehicle-incubated islets (Fig. 9I; n ≥ 3
independent experiments). In contrast, in Trpm3-deficient islets,
no additional insulin release was observed after incubation with
the TRPM3 agonists (Fig. 9I). In addition, no significant dif-
ferences between WT and Trpm3 knockout islets were observed
following incubation with a high-glucose– or high-K+–containing
solution (Fig. 9I). These data demonstrate that stimulation of
pancreatic islets by CIM0216 induces the release of insulin in
a TRPM3-specific manner.
Discussion
In this paper, we have presented a newly identified and potent
activator of TRPM3, CIM0216, which has the unique property to
open distinct cation permeation pathways by itself and represents,
Fig. 7. Neuronal and nocifensive responses to CIM0216. (A) Amplitude of
currents at ±80 mV of a patch-clamp recording in whole-cell configuration
during application of CIM0216 (1 μM) and La3+ (100 μM) in a TRPM3+/+ TGN.
(B) I–V relationship of the CIM0216-induced current at time points as in-
dicated in A. (Inset) CIM0216-induced current increase in the presence and
absence of La3+, obtained as the difference between two traces in B.
(C) Amplitude of currents at ±80 mV of a patch-clamp recording in whole-
cell configuration during application of CIM0216 (1 μM) in a TRPM3−/− TGN.
(D) Total number of behavioral responses (paw licks and lifts within 2 min)
in response to intraplantar injection of vehicle (vhc; 0.5% DMSO), PS
(15 nmol/paw), CIM0216 (2.5 nmol/paw), or capsaicin (Caps; 0.5 nmol/paw) in
WT mice (black bars) and TRPM3−/− mice (red bars). n = 9 animals for each
genotype. Data are presented as mean ± SEM. The black line represents the
unpaired t test; the blue bar, the paired t test. *P < 0.05; **P < 0.01.
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to our knowledge, the most potent activator of TRPM3 identi-
fied so far. The use of this agonist has allowed us to further
investigate the physiological consequences of the opening of
TRPM3 in vivo. In particular, we demonstrate that activation of
TRPM3 can evoke the release of CGRP from sensory nerve
terminals in the skin, implying a potential role in the initiation of
neurogenic inflammation. Furthermore, our present results show
that potent TRPM3 agonists can act as secretagogues triggering
insulin release from pancreatic islets, even at low extracellular
glucose levels.
Our results demonstrate that CIM0216 activates TRPM3 in
a membrane-delimited manner, because CIM0216 is capable of
activating the channel in the inside-out patch-clamp configura-
tion. We and other investigators have reported that PS acts on
TRPM3 only when applied at the extracellular side of the
membrane (4, 5, 20), whereas CIM0216 is active from the in-
tracellular side as well. Of note, a similar intracellular interaction
side on TRPM3 has been suggested for Clt (5). The Clt-induced
block of TRPM3 currents after stimulation by CIM0216 might
point to a possible competition between Clt and CIM0216
for the same interaction side; however, further investigation is
needed to identify the CIM0216 interaction side on TRPM3.
We identify CIM0216 as a very potent activator of TRPM3.
At first sight, there is very little structural analogy between
CIM0216 and known TRPM3 ligands, such as PS or nifedipine.
A previous study reported that a negative charge at position C3
of the steroid PS is required for TRPM3 activation (20); however,
no acidic substituents are present on CIM0216, and as such, the
compound does not have a negative charge. Moreover, we show
evidence for a role of CIM0216 as a modulator of PS-induced
TRPM3 responses, as is described for Clt. The structure of Clt is
a basic compound comprising four aromatic rings centered around
a carbon atom. CIM0216 has the same basic properties and com-
prises three aromatic ring systems around a central linking moiety.
We found that activation of TRPM3 by CIM0216 stimulation
induced an inwardly and outwardly rectifying current in both
TRPM3-overexpressing cells and cells that endogenously express
TRPM3. This I–V relationship differs from the outwardly rec-
tifying TRPM3 current described for other TRPM3 agonists like
PS and nifedipine and for heat (3, 4, 20), but is similar to that
measured on combined application of endogenous neurosteroids
and exogenous chemicals such as Clt (5). The properties of the
inwardly rectifying component indicate that CIM0216 itself is
able to open the same alternative pathway observed after the
combined application of PS and Clt. The large inward current,
which under physiological conditions is carried mainly by Na+,
makes CIM0216 an ultrapotent TRPM3 agonist, especially in ex-
citable cells, such as sensory neurons and pancreatic β cells. In these
cells, robust Na+ influx may facilitate membrane depolarization and
concomitant Ca2+ influx via voltage-gated Ca2+ channels, thereby
augmenting intracellular Ca2+ signals and vesicular release.
Using CIM0216, we have described a novel physiological
function of TRPM3 as a mediator of neuropeptide release and
neurogenic inflammation. In particular, we have shown that in-
cubation of mouse hind paw skin with different TRPM3 agonists
induces a dose-dependent CGRP release that was absent in the
presence of a specific TRPM3 blocker or in hind paw skin de-
rived from Trpm3-deficient mice. This finding suggests that
opening of TRPM3 can lead to CGRP-induced vasodilation and
vascular leakage, similar to what has been described for TRPV1
and TRPA1 (7, 21, 22). We note that the functional expression
of a Ca2+-permeable ion channel in a small subpopulation of C
and Aδ fibers does not constitute evidence that such channels are
involved in CGRP release, given that, for instance, TRPM8-
expressing neurons show no coexpression with typical markers of
nociceptor neurons, such as CGRP, substance P, and isolectin
B4, and TRPM8 activation is not known to cause neuropeptide
release (23). Previous studies have shown that application of PS
induces vasoconstriction, an effect blocked by pre-exposure to
a TRPM3-blocking antibody (24, 25). It should be noted that
these studies used relatively high PS doses and were performed
on aorta, which is poorly braided with CGRP fibers. Further
investigation of Trpm3-deficient mice will clarify the role of
TRPM3 in vascular smooth muscle contractility.
Several lines of evidence indicate that CIM0216-induced no-
ciceptive behavior and CGRP release is due to the activation of
TRPM3, and not to activation of other nociceptive transducers,
such as TRPV1 and TRPA1. First, no or very little stimulating
effects were observed in cells overexpressing TRPV1 and TRPA1
after stimulation by at least 10 μM CIM0216. Second, the majority
of the sensory neurons that responded to CIM0216 were also
positive for PS stimulation, known as a selective TRPM3 acti-
vator (4). Only a very limited fraction of neurons (∼10%) were
unresponsive to PS stimulation but positive for CIM0216 and
MO stimulation. Third, the number of CIM0216-sensitive noci-
ceptors was strongly reduced in TRPM3-deficient mice, and the
remaining responders could be blocked by the TRPA1 inhibitor
HC030031. Fourth, a similar high percentage of neurons (55%
of all neurons) responded to PS and CIM0216 stimulation in
neurons derived from Trpa1-deficient mice. Fifth, in contrast
Fig. 8. TRPM3 agonists release CGRP from skin nerve terminals. (A) PS increased the outflow of CGRP from skin preparations in a concentration-dependent
manner. No significant increase of CGRP release was detected in TRPM3−/− tissue. Asterisks refer to P < 0.01 between genotypes (n = 10 vs. 7, ANOVA and LSD
statistical tests). (B) CGRP release from WT skin during a 5-min incubation with CIM0216 at different concentrations (1, 5, 10, 50, and 100 μM) and capsaicin
(0.3 μM) for comparison. (C) CGRP release during consecutive 5-min periods (5 min baseline, next 5 min, etc.). CIM0216 (50 μM) was applied during the period
tagged 5–10 min to hind paw skin derived from WT mice (black; n = 7) and Trpm3-deficient mice (red; n = 4). In the presence of the TRPM3 blocker iso-
sakuranetin (5 μM), no significant CIM0216-induced CGRP release was observed in WT skin (blue). n = 7; same animals as above. *P < 0.01 between the WT
groups, ANOVA and Fisher’s least significant differences test.
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to WT mice, TRPM3-deficient mice did not react to CIM0216
injection into the hind paw, and incubation with CIM0216 did
not induce further CGRP release in hind paw skin. Sixth, a sim-
ilar CIM0216-induced CGRP release was observed in hind paw
skin of WT, TRPV1−/−, and TRPA1−/− knockout mice.
We also have illustrated the functional role of TRPM3 in
pancreatic cells and the involvement of TRPM3 in insulin re-
lease. Stimulation of isolated pancreatic islets by TRPM3 acti-
vators PS and CIM0216 induced a strong increase in intracellular
Ca2+ and current density and further insulin release, which was
fully lacking in TRPM3−/− cells. The first indications of the in-
volvement of TRPM3 in insulin release were reported by pre-
vious studies showing that PS led to a rapid Ca2+ influx and
enhanced insulin secretion from pancreatic islets (4). Remarkably,
no difference in calcium influx or insulin release was detected
between control and Trpm3-deficient mice after stimulation with
high glucose concentrations. In addition, TRPM3−/− mice and
TRPM3+/+ controls exhibited no obvious differences in basal
blood glucose levels (3). Taken together, these results suggest
only a minor role for TRPM3 in normal glucose-induced insulin
release, although the possibility that TRPM3 modulates insulin
release under specific (patho)physiological conditions cannot
be excluded.
In conclusion, our observations identify CIM0216 as the most
potent known agonist of TRPM3, with the unique property
of opening different ion permeation pathways of TRPM3 in-
dependent of other channel modulators. This novel agonist has
led to the identification of a role of TRPM3 in the release of
CGRP and insulin.
Materials and Methods
Cell Culture and Transfection. HEK293 cells stably expressing murine TRPM3
and nontransfected HEK293 were designed and cultured as described pre-
viously (3). DRG and TGN were isolated as described previously (26). Because
the RNA expression of TRPM3 varies very little between different ganglia
(27), DRG were isolated from along the entire vertebral column of the
mouse. Isolation of pancreatic islets and dissociation into single cells were
performed as described previously (28).
Animals. The TRPM3−/−, TRPV1−/−, and TRPA1−/− mice have been described
previously (3, 18, 29). The knockout strains were backcrossed at least six
times into the C57BL/6J background, and C57BL/6J mice served as WT con-
trols. Mice of all genotypes were housed under identical conditions, with
a maximum of five animals per cage, on a 12-h light–dark cycle and food and
water ad libitum. All experiments were performed using 8- to 12-wk-old
mice. Only male mice were used in the behavioral experiments.
Small-Molecule Library Screening. Small molecules were present in black 384-
well assay plates (Greiner) with buffer containing 138 mM NaCl, 5.4 mM KCl,
4 mM CaCl2, 2 mM MgCl2, 10 mM glucose, and 10 mM Hepes; pH 7.2 with
NaOH). HEK-TRPM3 and nontransfected HEK293 cells were loaded with 2 μM
Fluo-4 AM (Invitrogen) for 30 min, detached using trypsine, collected in
calcium-free medium (138 mM NaCl, 5.4 mM KCl, 2 mM MgCl2, 10 mM
glucose, and mM 10 Hepes; pH 7.2 with NaOH), and added to the assay
plate at ± 2,000 cells per well. The final CaCl2 concentration in the assay
solution was 2.4 mM. Fluorescence (excitation at 485 nm; emission at 535 nm)
was measured with an Envision fluorescence reader before and after the ad-
dition of 50 μM PS. All responses were normalized to the response to 50 μM PS
in the absence of small molecules.
Fluorescence Imaging and Electrophysiology. The protocol and imaging system
for standard Ca2+ measurements have been described elsewhere (26). The
standard imaging solution contained 150 mM NaCl, 10 mM Hepes, 2 mM
Fig. 9. CIM0216 induces TRPM3-dependent calcium and current increases and enhances insulin release from pancreatic islets. (A and B) Effect of CIM0216 on
intracellular [Ca2+] in islets derived from WT mice (A) and Trpm3−/− mice (B). The islets were bathed in a solution containing 3 mM glucose. PS (40 μM)-,
CIM0216 (1 μM)-, 10 mM glucose-, and high-K+ (50 mM)-containing solutions were added at the indicated time points. (C) Average increase in fluorescence
ratio (F350/F380) after stimulation with PS (40 μM), CIM0216 (1 μM), and 50 mM K+ in islets from WT and Trpm3−/− mice. n = 9 from three mice; ***P < 0.001,
unpaired t test. (D) Amplitude of currents at ±80 mV of a patch-clamp recording in whole-cell configuration during application of PS (40 μM), CIM0216 (1 μM),
and La3+ (100 μM) in a Trpm3+/+ isolated pancreatic islet cell. (E and F) I–V relationship of the PS-induced (E) and CIM0216-induced (F) currents at time points
as indicated in D. (G) Mean currents at ±80 mV of a patch-clamp recording in whole-cell configuration during application of PS (40 μM) and CIM0216 (1 μM) in
Trpm3−/− isolated pancreatic islet cells (n = 5). (H) Mean current increases at ±80 mV of a patch-clamp recording in whole-cell configuration during application
of PS (40 μM) or CIM0216 (1 μM) on Trpm3+/+ and Trpm3−/− pancreatic islet cells (n ≥ 5). (I) Insulin release after a 15-min incubation with vehicle (vhc, DMSO),
PS (100 μM), CIM0216 (5 μM and 20 μM), high K+ (50 mM), and glucose (Gluc; 20 mM) in WT mice (black bars) and TRPM3−/− mice (red bars). n = 4 from four
independent measurements; **P < 0.01, unpaired t test.
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CaCl2, and 1 mM MgCl2 (pH 7.4 with NaOH). For measurements on sensory
neurons, cells were considered responders if the fluorescence ratio in-
creased by 0.05 above the basal value on compound application. Non-
responsive cells that did not respond to application of 50 mM KCl were
excluded from the analysis.
For [Ca2+]i measurements in isolated pancreatic islets, islets were loaded
with 1 μM Fura-2 for 1 h at 37 °C in culture medium. [Ca2+]i from the Fura-
2–loaded islets was measured by monitoring the fluorescence ratio (F350/
F380) every 2 s (after correction for background fluorescence) using a mono-
chromator-based system consisting of a Polychrome IV monochromator (FEI
Munich) with an additional TILL Photonics photomultiplier, both controlled by
Pulse software (HEKA Elektronik). Standard extracellular solution for Ca2+ im-
aging measurements contained 120 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2,
1.2 mM MgCl2, and 10 mM Hepes (pH 7.4 with NaOH), with various con-
centrations of glucose added as indicated.
Whole-cell membrane currents and inside-out currents were measured
with an EPC-10 patch-clamp amplifier and PatchMasterPro Software (HEKA
Elektronik). Current measurements were performed at a sampling rate of
20 kHz, and currents were digitally filtered at 2.9 kHz. For whole-cell
recordings on HEK293 cells, the standard extracellular solution contained 150
mM NaCl, 1 mM MgCl2, and 10 mM Hepes (pH 7.4 with NaOH), and the
standard internal solution contained 100 mM CsAsp, 45 mM CsCl, 10 mM
EGTA, 10 mM Hepes, and 1 mM MgCl2 (pH 7.2 with CsOH). In experiments
allowing Ca2+-dependent desensitization of TRPM3, Mg2+ was replaced by
Ca2+ in the extracellular solution, and Cs+ was replaced by Na+ in the pipette
solution. Whole-cell current recordings on primary cells were performed using
similar solutions, supplemented with 10 mM glucose in the external solution for
pancreatic islets and 10mMglucose and 100 nM TTX in the external solution and
5 mM TEA in the internal solution for sensory neurons. The standard patch pi-
pette resistance was between 2.5 MΩ and 5 MΩ when filled with pipette solu-
tion. Between 50% and 70% of the series resistance was compensated.
Behavior. PS (250 μM), CIM0216 (50 μM), and capsaicin (10 μM) were dissolved
in PBS + 0.1% DMSO. An intraplantar injection of 20 μL was performed using
a 30G needle coupled to a Hamilton syringe, and behavior was recorded.
Experiments were performed during the light cycle. Nocifensive behavior
was quantified during the first 2 min after injection (3). Execution and
analysis of behavioral experiments were done blinded, that is, without
knowledge of the mouse genotype (3). All animal experiments were carried
out in accordance with the European Union Community Council guidelines
and approved by the local Ethics Committee.
CGRP Release. Skin flaps of bothmouse hairy hind paws were excised from the
lower leg and foot and wrapped around acrylic rods, with the corium side
exposed as described previously (30). Samples were placed in carbogen-
gassed synthetic interstitial fluid (SIF) inside a shaking bath set to 32 °C for
a washout period of 30 min. Skin flaps were then passed consecutively
through a set of four glass tubes containing 700 μL of SIF, with each in-
cubation step lasting 5 min. The first two incubation steps were performed
to determine basal CGRP release and variability at 32 °C. The third in-
cubation step assessed heat (47°, 50°, or 52 °C) or chemically induced CGRP
release. In the case of chemical treatment, one hind paw skin was stimu-
lated with the TRPM3 agonist CIM0216 (50 μM in SIF) and the other was
exposed to CIM0216 together with the TRPM3 blocker isosakuranetin
(5 μM). The fourth incubation step assessed recovery from the response in
SIF at 32 °C. The CGRP content of the incubation fluid was measured using
commercial enzyme immunoassay kits with a detection threshold of 5 pg/mL
(Bertin Pharma). The EIA plates were photometrically analyzed using a
microplate reader (Dynatech). All results are presented as measured by the
EIA in pg CGRP/mL SIF. To reduce interindividual variability and day-to-day
baseline variability, the data were normalized to the second individual
baseline value (before stimulation). This value was subtracted from all four
data points of a typical experiment, so that only the absolute change in
CGRP release (Δ pg/mL) is displayed in the figures.
Insulin Release. The isolated islets were used immediately after isolation.
Insulin release was measured as described previously (28) using a commer-
cially available ELISA kit (Crystal Chem).
Data Analysis. Electrophysiological data were analyzed using WinASCD
software (Guy Droogmans, Catholic University of Leuven) and Origin 8.6
(OriginLab). Origin 8.6 was also used for statistical analysis and data
display. Pooled data of continuous parameters are expressed as mean ±
SEM from n biological replicates. The Student paired or unpaired two-
tailed t test was used for statistical comparisons of two datasets. For CGRP
measurements, statistical comparisons were performed using Statistica 7
software (Statsoft). All-time series of experimental values were first ana-
lyzed for the effect of stimulation (heat, chemical) compared with baseline,
using the nonparametric Wilcoxon matched-pairs test. The baseline-nor-
malized (i.e., Δ) CGRP values were entered into a one-way ANOVA, followed
by Fisher’s least significant difference test, focusing on the peak values of
stimulated CGRP release. P < 0.05 was considered statistically significant. P <
0.01 is indicated by double asterisks; P < 0.001, by triple asterisks. Data
points represent mean ± SEM of the given number (n) of identical experi-
ments. Unless indicated otherwise, experiments were performed at room
temperature (23 ± 1 °C).
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Fig. S1. Stimulation of mTRPM3 by CIM0216 induces a [Ca2+]i influx derived from the extracellular medium. (A) Mean fluorescent increase in nontransfected
HEK293 (NT) and HEK-TRPM3 cells after stimulation by PS (50 μM) and CIM0216 (10 μM). Data are mean ± SEM; n = 4. (B) Time course of Ca2+ imaging
measurements in HEK-TRPM3 cells during application of PS (40 μM) and CIM0216 (1 μM) in the absence of extracellular calcium. n > 500 in at least three
independent measurements. (C) Mean Ca2+ increase in HEK-TRPM3 and nontransfected (NT) HEK293 cells on stimulation with either PS (40 μM) or CIM0216
(1 μM) in the presence (2 mM) or absence of extracellular calcium.
Fig. S2. CIM0216 activates human TRPM3 in a dose-dependent manner. (A) Time course at ±80 mV of a patch-clamp recording in whole-cell configuration
showing CIM0216 dose-dependent activation of TRPM3 currents in HEK293 cells transiently transfected with human TRPM3. (B) I–V relationships at the time
points indicated in A.
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Fig. S3. Selectivity of CIM0216 against other TRPM family members. (A) Time course at ±80 mV of a patch-clamp recording in whole-cell configuration of
HEK293 cells transiently transfected with human TRPM1. At the indicated time points, PS (40 μM) and CIM0216 (10 μM) were added. (B) Time course at ±80 mV
of a patch-clamp recording in whole-cell configurations of HEK293 cells transiently transfected with human TRPM2. At the indicated time points, CIM0216
(10 μM) was added or all cations were exchanged for NMDG+ in the extracellular solution. For activation of TRPM2, the pipette solution contained ADP-ribose
(300 μM). (C) Time course at ±80 mV of a patch-clamp recording in an inside-out configuration of HEK293 cells stably expressing human TRPM4. At the in-
dicated time points, CIM0216 (10 μM) was added before or during stimulation with 1 mM Ca2+. (D) Time course at ±80 mV of a patch-clamp recording in whole-
cell configuration of HEK293 cells stably expressing murine TRPM5. At the indicated time points, CIM0216 (10 μM) was added. To activate TRPM5, the pipette
solution contained Ca2+ (1 μM), adjusted by adding appropriate amounts of CaCl2 to the 10 mM EGTA-containing solution. (E and F) Time course at ±80 mV of
a patch-clamp recording in whole-cell configuration of HEK293 cells transiently transfected with human TRPM6 (E) or murine TRPM7 (F). At the indicated time
points, CIM0216 (10 μM) or Mg2+ (10 mM) was added.
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Fig. S4. Selectivity of CIM0216 against other sensory TRP channels. (A and B) Time course at ±80 mV of a patch-clamp recording in whole-cell configuration of
HEK293 cells transiently transfected with human TRPV1 (A) and human TRPM8 (B). At the indicated time points, CIM0216 (10 μM) was added before or during
stimulation by 1 μM capsaicin (A) or 100 μM menthol (B). (C) Time course at ±80 mV of a patch-clamp recording in whole-cell configuration of CHO cells stably
transfected with murine TRPA1. At the indicated time points, different doses of CIM0216 (1, 10, 50, 70, and 100 μM) and MO (100 μM) were added. (D) I–V
relationships at the time points indicated in C.
Fig. S5. The rectification pattern of CIM0216-induced TRPM3 currents is not dose-dependent. Shown are rectification patterns of CIM0216-induced TRPM3
currents at five different concentrations in HEK-TRPM3 cells, derived by plotting the currents at +150 mV against the currents at −150 mV.
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Fig. S6. Conductance curves of WT TRPM3, and TRPM3 mutant channels, in response to PS and CIM0216. (A and B) Steady-state G–V relationships obtained in
HEK-TRPM3 cells in the presence of CIM0216 (1 μM) or PS (40 μM), with conductances normalized for each compound to the maximal conductance at +150mV (A)
or not normalized (B). n = 6. Fit functions are presented as Boltzmann fit. (C and D) Steady-state G–V relationships obtained in HEK293 cells transiently
transfected with the TRPM3 pore mutant E1057C in the presence of CIM0216 (1 μM) or PS (40 μM), with conductances normalized for each compound to the
maximal conductance at +150 mV (C) or not normalized (D). n ≥ 8. (E and F) Steady-state G–V relationships obtained in HEK293 cells transiently transfected
with the S4 mutant W982R in the presence of CIM0216 (1 μM) or PS (40 μM), with conductances normalized for each compound to the maximal conductance at
+150 mV (E) or not normalized (F). n ≥ 5. The 0-mV conductance was extrapolated from the Boltzmann fit.
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Fig. S7. Effect of La3+ on the voltage dependency of the gating-pore current. (A) I–V relationships of TRPM3-induced currents after stimulation by CIM0216 in
the presence and absence of La3+ (100 μM). (B) G–V relationships obtained from the current traces shown in A. The region between −5 mV and +5 mV was
excluded from the analysis. Dashed lines show a Boltzmann function fitted to the rightmost part of the G–V curve (+5 to +120 mV). (C) G–V curve of the
inwardly rectifying current component. These curves were obtained by subtracting the fitted Boltzmann functions from the total G–V curves shown in B.
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Fig. S8. TRPM3 channels can permeate ions through different pathways. (A) PS-activated TRPM3 currents are outwardly rectifying but develop an inwardly
rectifying component in response to a combination of the agonist (PS) and the channel modulator Clt. The inwardly rectifying component is not carried by the
central pore and is likely to be carried by an alternative ion permeation pathway. Application of the open pore blocker La3+ blocks the current through the
central pore. (B) CIM0216-activated TRPM3 currents are strongly inwardly and outwardly rectifying, even in the absence of the channel modulator Clt.
The typically CIM0216-induced rectification pattern is likely to be carried by the opening of the central pore and the alternative pore. La3+ blocks the central
pore, whereas the alternative ion permeation pathway is unaffected.
Fig. S9. Selectivity of CIM0216 in sensory neurons. Representative traces showing typical patterns of intracellular Ca2+ in DRG and TGN from TRPM3−/− animals
in response to CIM0216 (1 μM), the TRPA1 blocker HC030031 (10 μM), MO (100 μM), capsaicin (Cap; 1 μM), and K+ (50 mM). All sensory TRPM3−/− neurons
responding to CIM0216 could be blocked by application of HC030031.
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Fig. S10. PS induces CGRP release in the skin preparations of TRPV1−/−- and TRPA1−/−-deficient mice. (A) PS (200 μM) evoked similar increases in the release of
CGRP from TRPV1−/− (n = 5) and TRPA1−/− (n = 9) knockout skin preparations compared with WT skin (n = 7). (B) CIM0216 (50 μM) induced similar increases in
CGRP release in skin preparations from WT and TRPV1−/− TRPA1−/− double-knockout mice (n = 4).
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